Literature DB >> 2848776

Neuromuscular blocking agents.

C J Lingle1, J H Steinbach.   

Abstract

Clearly, many aspects of the action of neuromuscular blockers remain poorly understood at the molecular level. In the case of competitive blockers, blockade of EPPs by competitive binding to the ACh receptor site accounts for the most clinically important aspect of blockade. Although train-of-four fade produced by curare and some other competitive agents probably represents a presynaptic action, the molecular mechanisms underlying this effect have not been addressed. Depolarizing blockade is inherently more complicated than competitive blockade. Simple depolarization and inactivation of the mechanism for generation of the action potential probably account for the major clinical effect seen in phase I block. Furthermore, the relative balance between activation of channels and desensitization may also provide a qualitative explanation for phase II block and tachyphylaxis. However, effects that are more likely to be explained by presynaptic actions of depolarizing blockers have also been described, and it is not yet possible to assess quantitatively whether the rates of onset of the different postsynaptic actions can account for most aspects of depolarizing block. This discussion has raised several issues which need to be addressed in future studies. 1. What are the presynaptic effects of cholinergic drugs? Do these drugs act through a specific receptor or, on other ion channels in the terminal membrane, or do they operate by mechanisms distinct from effects on membrane conductance? Can any of the observations be explained by indirect effects mediated through postsynaptic ACh receptors, e.g., K+ release? 2. What are the factors that influence variability in sensitivity to neuromuscular blockers among species, muscles within species, and during development? Many of the potential factors, e.g., differences in safety factor, resting conductances, ACh receptor type, and differences in the presence and absence of presynaptic receptors, have been outlined, but definitive tests of the contribution of any particular mechanisms are lacking. 3. Does modulation of desensitization play a role in any components of neuromuscular blockade? 4. Can trapping of blocking agents in ion channels in some cases account for slowly reversible components of blockade? 5. Can closed-channel block provide an effective mechanism of neuromuscular block?

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848776     DOI: 10.1097/00004311-198802640-00007

Source DB:  PubMed          Journal:  Int Anesthesiol Clin        ISSN: 0020-5907


  9 in total

1.  Neonatal partial denervation results in nodal but not terminal sprouting and a decrease in efficacy of remaining neuromuscular junctions in rat soleus muscle.

Authors:  J L Lubischer; W J Thompson
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

2.  Changes in aging mouse neuromuscular junctions are explained by degeneration and regeneration of muscle fiber segments at the synapse.

Authors:  Yue Li; Young il Lee; Wesley J Thompson
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

3.  Lambert-Eaton sera reduce low-voltage and high-voltage activated Ca2+ currents in murine dorsal root ganglion neurons.

Authors:  K D García; M Mynlieff; D B Sanders; K G Beam; J P Walrond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

4.  Axon withdrawal during synapse elimination at the neuromuscular junction is accompanied by disassembly of the postsynaptic specialization and withdrawal of Schwann cell processes.

Authors:  S M Culican; C C Nelson; J W Lichtman
Journal:  J Neurosci       Date:  1998-07-01       Impact factor: 6.167

5.  Nerve terminal growth remodels neuromuscular synapses in mice following regeneration of the postsynaptic muscle fiber.

Authors:  Yue Li; Wesley J Thompson
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

6.  A novel labeling approach identifies three stability levels of acetylcholine receptors in the mouse neuromuscular junction in vivo.

Authors:  Siegfried Strack; Yvonne Petersen; Anika Wagner; Ira V Röder; Marina Albrizio; Markus Reischl; Irene U Wacker; Christoph Wilhelm; Rüdiger Rudolf
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

7.  Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation.

Authors:  Matthew R Lewin; Philip Bickler; Tom Heier; John Feiner; Lance Montauk; Brett Mensh
Journal:  Clin Case Rep       Date:  2013-07-24

Review 8.  Synaptic Secretion and Beyond: Targeting Synapse and Neurotransmitters to Treat Neurodegenerative Diseases.

Authors:  Ziqing Wei; Mingze Wei; Xiaoyu Yang; Yuming Xu; Siqi Gao; Kaidi Ren
Journal:  Oxid Med Cell Longev       Date:  2022-07-25       Impact factor: 7.310

Review 9.  Sugammadex as a reversal agent for neuromuscular block: an evidence-based review.

Authors:  Stefan Josef Schaller; Heidrun Fink
Journal:  Core Evid       Date:  2013-09-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.